These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25768401)

  • 1. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
    Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
    Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
    Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
    Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
    Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
    Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
    Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
    [No Abstract]   [Full Text] [Related]  

  • 10. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
    Verstovsek S; Savona MR; Mesa RA; Dong H; Maltzman JD; Sharma S; Silverman J; Oh ST; Gotlib J
    Br J Haematol; 2017 Mar; 176(6):939-949. PubMed ID: 28220932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
    Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
    Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T
    Br J Haematol; 2010 Aug; 150(4):446-55. PubMed ID: 20560970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
    Tefferi A
    Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
    Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
    Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.